Z-c(=o)-o-y Wherein Z Is Hydrogen Or An Organic Radical Bonded To The C(=o) By A Carbon And Y Is An Organic Radical Bonded To The Oxygen By A Carbon Patents (Class 514/529)
  • Patent number: 11135296
    Abstract: Pharmaceutical compositions and dosage forms of (N,N-diethylcarbamoyl)methyl methyl (2E)but-2-ene-1,4-dioate and/or methyl 4-morpholin-4-ylbutyl (2E)but-2-ene-1,4-dioate, containing low levels of certain impurities are disclosed.
    Type: Grant
    Filed: May 15, 2018
    Date of Patent: October 5, 2021
    Assignee: Arbor Pharmaceuticals, LLC
    Inventors: Suresh Kumar Manthati, Sami Karaborni, Wei Chen
  • Patent number: 11019830
    Abstract: The present invention relates to a composition comprising vegetable oil, caramel and one or more phenolic compounds. The caramel and one or more phenolic compounds together prevent oxidation of the vegetable oil, such that the amount of EDTA in the composition can be reduced. The caramel has been heated such that it does not impart a dark colour to the composition. The invention also relates to a method to prepare the composition. Finally the invention relates to use of caramel and one or more phenolic compounds to decrease the oxidation of vegetable oil.
    Type: Grant
    Filed: June 7, 2016
    Date of Patent: June 1, 2021
    Assignee: Conopco Inc.
    Inventors: Parag Acharya, Jadwiga Malgorzata Bialek, Johannes Hendrikus Maria van den Broek, Franciscus Johannes H M Jansen
  • Patent number: 10772899
    Abstract: Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said compositions and methods comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from meibomian gland dysfunction.
    Type: Grant
    Filed: September 5, 2019
    Date of Patent: September 15, 2020
    Assignee: AZURA OPHTHALMICS LTD.
    Inventors: Yair Alster, Omer Rafaeli, K. Angela MacFarlane, Cary Reich, Shimon Amselem, Doron Friedman
  • Patent number: 10709897
    Abstract: The present invention provides compositions comprising energy (e.g., light) absorbing submicron particles (e.g., nanoparticles comprising a silica core and a gold shell) and methods for delivering such particles via topical application. This delivery is facilitated by application of mechanical agitation (e.g. massage), acoustic vibration in the range of 10 Hz-20 kHz, ultrasound, alternating suction and pressure, and microjets. The method of treatment is performed and then, depending upon the desired clinical outcome, repeated after a treatment response interval has elapsed.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: July 14, 2020
    Assignee: Sebacia, Inc.
    Inventors: Anthony V. Lando, Dilip Paithankar, Erin C. Keller, Todd J. Meyer
  • Patent number: 10689362
    Abstract: A compound, capable of inhibiting kinases, for the treatments of diseases or disorders mediated by such kinases, has a structure of formula (I): or a stereoisomer, a tautomer, a pharmaceutically acceptable salt thereof. The compound can be used in the treatments of diseases or conditions mediated by CSF-1R, c-KIT, FLT3, or PDGFR kinases. Such diseases or conditions may include cancers, autoimmune diseases, and bone resorptive diseases.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: June 23, 2020
    Assignee: Development Center for Biotechnology
    Inventors: Shao-Zheng Peng, Chu-Bin Liao, Hung-Kai Chen, Chen-Hsuan Ho, Hung-Jyun Huang, Shian-Yi Chiou
  • Patent number: 10561702
    Abstract: The present invention relates to a novel use of proline containing dipeptides for the prevention and/or treatment of skin conditions associated with altered, damaged or malfunctioning sebaceous glands.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: February 18, 2020
    Assignee: DSM IP ASSETS B.V.
    Inventors: Remo Campiche, Dominik Imfeld, Eileen Jackson, Eliane Ursula Wandeler
  • Patent number: 10549130
    Abstract: A bath salt contains granular magnesium chloride material that is uniformly coated with a fragrance enhancing material and/or a colorant. The bath salt can include magnesium sulfate material and mineral salt material. The bath salt can be made by mixing the magnesium chloride material and starch material to form an intermediate mixture. The colorant and the intermediate mixture are mixed together to form a uniformly colored bath salt.
    Type: Grant
    Filed: January 26, 2015
    Date of Patent: February 4, 2020
    Assignee: Nutraceutical Corporation
    Inventors: David E. Bunch, Frank W. Gay, II, Autumn Blum, Antoine Nkameni
  • Patent number: 10548864
    Abstract: The invention features all-trans retinoic acid (ATRA)-related compounds capable of associating with Pin1 and methods of treating a proliferative disorder characterized by elevated Pin1 marker levels, Pin1 degradation, and/or reduced Pin1 Ser71 phosphorylation in a subject by administering an ATRA-related compound. The invention also features methods of treating proliferative disorders, autoimmune diseases, and addiction conditions (e.g., diseases, disorders, and conditions characterized by elevated Pin1 marker levels) by administering an ATRA-related compound in combination with another therapeutic compound.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: February 4, 2020
    Assignee: Beth Israel Deaconess Medical Center, Inc.
    Inventors: Kun Ping Lu, Xiao Zhen Zhou, Shuo Wei, Lijun Sun, Michelle Lynn Hall
  • Patent number: 10493058
    Abstract: In various embodiments, the present invention provides compositions and methods for treating and/or preventing a cardiovascular-related disease in subject in need thereof.
    Type: Grant
    Filed: June 3, 2015
    Date of Patent: December 3, 2019
    Assignee: Amarin Pharmaceuticals Ireland Limited
    Inventor: Jonathan Rowe
  • Patent number: 10336693
    Abstract: An oseltamivir analog and nanoparticles having the analog bound thereto, of the present invention, strongly bind to oseltamivir-resistant influenza virus, and thus, the use of the same can allow detection of oseltamivir-resistant influenza viruses quickly and conveniently with the naked eye. Therefore, the present invention can be favorably utilized in promptly establishing a therapeutic schedule for a patient infected with influenza viruses.
    Type: Grant
    Filed: July 4, 2016
    Date of Patent: July 2, 2019
    Assignee: Korea Research Institute of Bioscience and Biotechnology
    Inventors: Juyeon Jung, Eun Kyung Lim
  • Patent number: 10238580
    Abstract: A solid cosmetic product includes an inner non-effervescent material having at least a coloring and a solid carrier material. The solid carrier material is a powder and the non-effervescent material does not effervesce on contact with water. An outer effervescent material is capable of effervescence on contact with water and envelops the inner non-effervescent material.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: March 26, 2019
    Assignee: COSMETIC WARRIORS LIMITED
    Inventors: Mark Constantine, Margaret Joan Constantine, Helen Elizabeth Ambrosen
  • Patent number: 10238610
    Abstract: Compositions of and methods for using synthetic retinoids as retinoid replacements and opsin agonists are provided.
    Type: Grant
    Filed: December 7, 2012
    Date of Patent: March 26, 2019
    Assignee: University of Washington
    Inventors: Krzysztof Palczewski, David A. Saperstein
  • Patent number: 10117845
    Abstract: Compositions of and methods for using synthetic retinal derivatives as retinoid replacements and opsin agonists are provided.
    Type: Grant
    Filed: July 19, 2016
    Date of Patent: November 6, 2018
    Assignee: University of Washington
    Inventors: Krzysztof Palczewski, Matthew Batten
  • Patent number: 10059734
    Abstract: Disclosed are a compound and a pharmaceutical composition that exhibit an excellent drug efficacy against a tumor, in particular a tumor which has acquired resistance to gemcitabine. Specifically, provided is a thionucleoside derivative represented by General Formula [1] (in the formula, R1 represents a hydroxyl group which may be protected, a C1-20 alkoxy group which may be substituted, or the like; R2 represents a C1-20 alkoxy group which may be substituted, a C3-8 cycloalkoxy group which may be substituted, or the like; and R3 represents a hydrogen atom or the like); or a salt thereof. Further, provided is a pharmaceutical composition containing such a thionucleoside derivative or a salt thereof.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: August 28, 2018
    Assignee: FUJIFILM Corporation
    Inventors: Hidenobu Kuniyoshi, Daisuke Nakagawa, Takuya Matsumoto, Yuji Yoshimitsu
  • Patent number: 9949941
    Abstract: Sustained release oral dosage forms of a gabapentin prodrug, 1-{[(?-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid, are disclosed. The dosage forms are useful for treating or preventing diseases and disorders for which gabapentin is therapeutically effective.
    Type: Grant
    Filed: November 22, 2016
    Date of Patent: April 24, 2018
    Assignee: XENOPORT, INC.
    Inventors: Kenneth C. Cundy, Srikonda Sastry, Manshiu Leung, Balaji V. Kadri, Paul E. Stach
  • Patent number: 9855239
    Abstract: A method of treating or preventing age-related retinal dysfunction involves administering to a patient a pharmaceutically effective amount of a synthetic retinal derivative repeatedly over a duration of at least about 3 months. Effective synthetic retinal derivatives include 9-cis-retinyl esters, 11-cis-retinyl esters, derivatives and congeners thereof, and combinations thereof. Suitable ester substituents include carboxylates of C1-C10 monocarboxylic acids and C2-C22 polycarboxylic acids.
    Type: Grant
    Filed: July 26, 2016
    Date of Patent: January 2, 2018
    Assignee: University of Washington
    Inventors: Tadao Maeda, David Saperstein, Krzysztof Palczewski
  • Patent number: 9777248
    Abstract: Aqueous hard surface cleaners and concentrates are disclosed. In one aspect, the cleaners comprise water, a monounsaturated C8-C14 fatty N,N-dialkylamide, and at least one anionic, cationic, nonionic, or amphoteric surfactant. The cleaners have a pH within the range of 6.0 to 9.0. Dilutable hard surface cleaner concentrates comprising the monounsaturated N,N-dialkylamide and a surfactant are also disclosed. Also included are aqueous hard surface cleaners which comprise a monounsaturated N,N-dialkylamide, and which by measure of ASTM D4488-95 A5 soil, provide superior percent cleaning at a pH less than 10 than they do at pH 10 and higher. Surprisingly, when a monounsaturated C8-C14 fatty N,N-dialkylamide is included in the aqueous hard surface cleaner or concentrate, rapid and thorough cleaning performance can be achieved even at relatively neutral pH. Consequently, the hard surface cleaners are effective on greasy soils, including baked-on soils, despite their low alkalinity.
    Type: Grant
    Filed: September 5, 2013
    Date of Patent: October 3, 2017
    Assignee: Stepan Company
    Inventors: Ronald A. Masters, Wilma Gorman
  • Patent number: 9434910
    Abstract: A solution having improved mold and mildew stain removing properties on hard surfaces, that is easier to handle (less corrosive and less malodorous) and that is environmentally friendly. The mold and mildew stain removing solution includes the following components: a surfactant selected from the group consisting of alcohol ethoxylates, alkyl sulfates, alkyl ether sulfates, alpha olefin sulfonates, alkyl phosphates, alkyl amidopropyl betaines, alkyl betaines, amphoacetates, amphoproprionates, amphosulfonates, amine oxides, alkanolamides, sulfosuccinates, and sultaines, a solvent, and at least one chelating agent. The solution may further comprise a hydrotrope, a diluent, a preservative, and/or a fungicide. The surfactant is preferably an alcohol ethoxylate. The hydrotrope is preferably lauramine oxide. The solvent is preferably a glycol ether. The chelating agents are preferably sodium gluconate and a solution of the trisodium salt of methyl glycine diacetic acid.
    Type: Grant
    Filed: January 16, 2013
    Date of Patent: September 6, 2016
    Assignee: Jelmar, LLC
    Inventor: Rosemary Gaudreault
  • Patent number: 9408821
    Abstract: A method of treating or preventing age-related retinal dysfunction involves administering to a patient a pharmaceutically effective amount of a synthetic retinal derivative repeatedly over a duration of at least about 3 months. Effective synthetic retinal derivatives include 9-cis-retinyl esters, 11-cis-retinyl esters, derivatives and congeners thereof, and combinations thereof. Suitable ester substituents include carboxylates of C1-C10 monocarboxylic acids and C2-C22 polycarboxylic acids.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: August 9, 2016
    Assignee: University of Washington
    Inventors: Tadao Maeda, David Saperstein, Krzysztof Palczewski
  • Patent number: 9278920
    Abstract: Compounds selected from the group of N-unsubstituted or N-alkylated or N-acylated 14-O-[(amino(C0-4)alkyl-hydroxy-cycloalkyl- or bicycloalkylsulfanyl)-acetyl]-mutilins which are 14-O-[(amino(C0-4)alkyl-hydroxy-cyclobutylsulfanyl)-acetyl]-mutilins, 14-O-[(amino(C0-4)alkyl-hydroxy-cyclopentylsulfanyl)-acetyl]-mutilins, 14-O-[(amino(C0-4)alkyl-hydroxy-cycloheptylsulfanyl)-acetyl]-mutilins, 14-O-[(amino(C0-4)alkyl-hydroxy-cyclooctylsulfanyl)-acetyl]-mutilins, or 14-O-[(amino(C0-4)alkyl-hydroxy-bicycloalkylsulfanyl)-acetyl]-mutilins, optionally in the form of a salt and/or a solvate, a pharmaceutical compositions comprising such compounds and their use as pharmaceuticals, e.g. for the treatment of microbial infections and for the treatment of acne, optionally in combination with other pharmaceutically active agents.
    Type: Grant
    Filed: August 11, 2011
    Date of Patent: March 8, 2016
    Assignee: Nabriva Therapeutics AG
    Inventors: Rosemarie Riedl, Klaus Thirring, Werner Heilmayer
  • Patent number: 9278901
    Abstract: This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis.
    Type: Grant
    Filed: May 13, 2015
    Date of Patent: March 8, 2016
    Assignee: United Therapeutics Corporation
    Inventors: Ken Phares, David Mottola, Roger Jeffs
  • Patent number: 9271495
    Abstract: A controlled release biocidal salt of a first component comprises a cation of a N?—(C1-C22) alkanoyl di-basic amino acid alkyl (C1-C22) ester cationic biocidal molecule and a second component comprising an anion of a monomeric anionic molecule having insignificant biocidal activity. The salt is characterized such that when the salt is exposed to an aqueous medium, the salt partially dissolves thereby releasing biocidal ions in an amount sufficient to exceed the MIC or MBC of a target bacteria being controlled, and further characterized as leaving a residual reservoir of undissolved salt capable of releasing more biocidal ions as the salt is consumed or otherwise removed from the environment encompassing the target bacteria. The preferred cationic biocidal molecule comprises N?-lauroyl-L-arginine ethyl ester (“LAE”).
    Type: Grant
    Filed: February 10, 2014
    Date of Patent: March 1, 2016
    Assignee: Nevada Naturals Inc.
    Inventors: Anthony J. Sawyer, Richard F. Stockel
  • Patent number: 9233091
    Abstract: A method of treating or preventing age-related retinal dysfunction involves administering to a patient a pharmaceutically effective amount of a synthetic retinal derivative repeatedly over a duration of at least about 3 months. Effective synthetic retinal derivatives include 9-cis-retinyl esters, 11-cis-retinyl esters, derivatives and congeners thereof, and combinations thereof. Suitable ester substituents include carboxylates of C1-C10 monocarboxylic acids and C2-C22 polycarboxylic acids.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: January 12, 2016
    Assignee: University of Washington
    Inventors: Tadao Maeda, David Saperstein, Krzysztof Palczewski
  • Patent number: 9199908
    Abstract: This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis.
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: December 1, 2015
    Assignee: United Therapeutics Corporation
    Inventors: Ken Phares, David Mottola, Roger Jeffs, Michael Wade
  • Patent number: 9150503
    Abstract: A crystalline form of a ?-aminobutyric acid analog, and methods of preparing same, are provided.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: October 6, 2015
    Assignee: XenoPort, Inc.
    Inventors: Tono Estrada, Stephen P. Raillard, Christine Frauenfelder, Uwe Zacher
  • Publication number: 20150141339
    Abstract: According to the invention there is provided a compound of formula (I): wherein R1, R2, R3 and n have meanings given in the description, or a pharmaceutically acceptable solvate, salt or prodrug thereof for use in the treatment of osteoporosis and/or osteopenia.
    Type: Application
    Filed: October 21, 2014
    Publication date: May 21, 2015
    Inventors: Stephen Hodges, Robin Soper
  • Publication number: 20150132260
    Abstract: The present invention relates to the use of the measure of anelloviral load for the determination of immunosuppression. More precisely, the present invention provides a method for characterizing the immunosuppressed or non-immunosuppressed status of a subject, comprising the steps of determining the anelloviral load from a biological sample of the said subject, and determining from the said comparison the immunosuppressed or non-immunosuppressed status. The determination of the immunosuppressed status of the subject can then be used to design or adapt a therapeutic treatment.
    Type: Application
    Filed: April 19, 2013
    Publication date: May 14, 2015
    Inventors: Marc Eloit, Justine Cheval, Charles Hebert, Marc Lecuit
  • Patent number: 9029415
    Abstract: The invention relates to a cooling mixture comprising or consisting of 5-methyl-2-(propane-2-yl)cyclohexyl-N-ethyloxamate and one, two, three or more certain polyols. It further relates to a cosmetic composition comprising such a cooling mixture or to a sanitary article comprising such a cooling mixture. The invention also relates to the use of certain polyols for enhancing the cooling effect of 5-methyl-2-(propane-2-yl)cyclohexyl-N-ethyloxamate on the skin or a mucous membrane, a method for generating an enhanced cooling effect of 5-methyl-2-(propane-2-yl)cyclohexyl-N-ethyloxamate on the skin or a mucous membrane as well as a method for generating a corresponding cooling mixture.
    Type: Grant
    Filed: June 14, 2011
    Date of Patent: May 12, 2015
    Assignee: Symrise AG
    Inventors: Thomas Küper, Heiko Oertling, Sabine Lange
  • Patent number: 9023891
    Abstract: Synergistic antimicrobial compositions are provided by combining effective amounts of N?-long chain alkanoyl di basic amino acid alkyl ester salts with glycerol monofatty acid esters resulting more effective anti-microbials and food preservatives.
    Type: Grant
    Filed: May 7, 2012
    Date of Patent: May 5, 2015
    Assignee: Nevada Naturals, Inc.
    Inventors: Richard F. Stockel, Anthony J. Sawyer
  • Publication number: 20150118165
    Abstract: The present invention relates to the use of at least one cyclohexanol ether derivative of the formula I as antimicrobial active compound or as anti-acne, antidandruff, deodorant or antiperspirant active compound, to preparations comprising these compounds, and to specific cyclohexanol ether derivatives.
    Type: Application
    Filed: April 5, 2013
    Publication date: April 30, 2015
    Applicant: Merck Patent GmbH
    Inventors: Thomas Rudolph, Sylvia Eisenberg
  • Patent number: 9012499
    Abstract: The present invention provides a pharmaceutical composition comprising: one or more excipients selected from sugars and sugar alcohols in which equilibrium water content is 1% by weight or less at 25° C. and at 70% relative humidity; and oseltamivir phosphate, wherein an amount of each of glucose and mannose contained in the sugars and sugar alcohols as impurities is 0.01% by weight or less.
    Type: Grant
    Filed: February 20, 2007
    Date of Patent: April 21, 2015
    Assignees: Chugai Seiyaku Kabushiki Kaisha, F. Hoffman-la Roche AG
    Inventors: Ryuji Kubota, Tomoaki Ohta, Tomoaki Hirayama, Hiroyuki Maeda, Christian Volland, Hans-Guenter Kaestle
  • Patent number: 8986722
    Abstract: It is an object of the present invention to provide a pest control composition capable of exerting a high effect on pests such as spider mites and aphids even at low concentration using a food/food additive with high safety to the human body and the environment. The present inventors have intensively studied to solve the above problem and found that, among polyglycerol fatty acid esters widely used as a food additive, a composition containing a polyglycerol fatty acid ester which has an HLB of 5 or less and is liquid at ordinary temperature and also a nonionic surfactant has a high effect on pests even at low concentration, and that the possibility for pests to develop resistance to the composition is extremely low, and the present invention has been completed.
    Type: Grant
    Filed: February 22, 2011
    Date of Patent: March 24, 2015
    Assignee: Nippon Kayaku Kabushiki Kaisha
    Inventors: Takeshi Suzuki, Takaaki Miyake, Kazuteru Ogawa
  • Patent number: 8980944
    Abstract: The present invention is directed to the use of EP2 and/or EP4 agonists as therapeutics for the treatment of diseases associated with influenza A viruses, such as for example H5N1 and mutations thereof.
    Type: Grant
    Filed: March 28, 2011
    Date of Patent: March 17, 2015
    Assignee: Gemmus Pharma Inc.
    Inventors: Daryl Faulds, William J. Guilford, Wolfgang Seifert
  • Publication number: 20150064282
    Abstract: Use of Neul sialidase inhibitors for the treatment of cancer as a monotherapy or in combination with known chemotherapeutics. Preferably, Neul sialidase inhibitors are oseltamivir phosphate or 2-deoxy-2,3-dehydro-N-acetylneuraminic acid (DANA) or analogues thereof.
    Type: Application
    Filed: November 4, 2011
    Publication date: March 5, 2015
    Inventors: Paul Zachary Josefowitz, Myron R. Szewczuk
  • Patent number: 8969397
    Abstract: Disclosed herein are systems and methods for contributing to the local treatment of pain. More specifically, the disclosed systems and methods contribute to the local treatment pain by inhibiting the NF?B family of transcription factors.
    Type: Grant
    Filed: February 5, 2010
    Date of Patent: March 3, 2015
    Assignee: Warsaw Orthopedic, Inc.
    Inventors: Eric N. Burright, Lisa L. Shafer, Bill McKay, John Zanella
  • Publication number: 20150051256
    Abstract: The present invention provides a medicament that suppresses (or mitigates) various neurological symptoms caused by a peripheral nerve disorder induced by an anti-cancer agent.
    Type: Application
    Filed: October 28, 2014
    Publication date: February 19, 2015
    Applicant: Takeda Pharmaceutical Company Limited
    Inventor: Naomi Kitamoto
  • Patent number: 8952062
    Abstract: Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient.
    Type: Grant
    Filed: March 6, 2013
    Date of Patent: February 10, 2015
    Assignee: Jazz Pharmaceuticals, Inc.
    Inventors: Harry Cook, Martha Hamilton, Douglas Danielson, Colette Goderstad, Dayton T. Reardan
  • Publication number: 20150025077
    Abstract: This invention relates to geranylgeranyl acetone (GGA) derivatives and the use of GGA, its isomers, and GGA derivatives in methods for inhibiting neural death, increasing neural activity, increasing axon growth and cell viability, and increasing the survival rate of subjects administered the GGA or GGA derivatives.
    Type: Application
    Filed: February 27, 2013
    Publication date: January 22, 2015
    Applicant: COYOTE PHARMACEUTICALS, INC.
    Inventors: Hiroaki Serizawa, Ankush B. Argade, Akash Datwani, Natalie Spencer, Yonghua Pan, Florian Ermini
  • Patent number: 8933121
    Abstract: The present invention discloses the potential of Calebin A in inhibiting adipogenesis and applications thereof in obesity management. The present invention elucidates the potential of Calebin A to favorably modulate biochemical markers associated with obesity. Notable biomodulatory properties of Calebin A include inhibiting leptin production, increasing adiponectin expression and inhibiting local (adipocyte) and systemic inflammation caused by pro-inflammatory cytokines Tumor Necrosis Factor (TNF-?), Interleukin-6 (IL-6) and Interleukin-1 (IL-1?).
    Type: Grant
    Filed: January 10, 2012
    Date of Patent: January 13, 2015
    Assignee: Sami Labs Limited
    Inventors: Muhammed Majeed, Anjali Pandey
  • Publication number: 20150005243
    Abstract: Methods that enable one to specifically measure the metabolic product of a particular molecule in relatively few cells, e.g. primary cells, are described. The methods involve optionally preloading cells with labeled substrate (e.g. labeled by 13C, 15N, or 31P). The methods allow for easy identification of metabolites that are differentially generated in cells of different phenotypes. The new methods for unbiased multi-dimensional NMR screening and rapid and efficient analysis of the NMR screening identify differentially expressed metabolites in different cell or tissue types. Analysis of the differentially expressed metabolites can present unique druggable targets to which small molecule therapeutics can be designed.
    Type: Application
    Filed: February 11, 2013
    Publication date: January 1, 2015
    Applicant: The Children's Medical Center Corporation
    Inventors: Elizabeth M. O'Day, Judy Lieberman, Gerhard Wagner
  • Publication number: 20140364400
    Abstract: The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a polyol wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti-inflammatory lipid mediators. This composition can be topically delivered to the ocular surface via a preparation, solution, gel, ointment, and/or strip and/or a contact lens.
    Type: Application
    Filed: August 22, 2014
    Publication date: December 11, 2014
    Inventor: Annabelle Gallois-Bernos
  • Patent number: 8906962
    Abstract: A method for treating hair loss in mammals uses compositions containing prostaglandin F analogs. The compositions can be applied topically to the skin. The compositions can arrest hair loss, reverse hair loss, and promote hair growth.
    Type: Grant
    Filed: September 23, 2013
    Date of Patent: December 9, 2014
    Assignee: Duke University
    Inventors: Mitchell A. deLong, John M. McIver, Robert S. Youngquist
  • Patent number: 8901169
    Abstract: In one aspect, the invention relates to compounds having the formula: where R1-R5 and X are as defined in the specification, or a pharmaceutically acceptable salt thereof. These compounds have neprilysin inhibition activity. In another aspect, the invention relates to pharmaceutical compositions comprising such compounds; methods of using such compounds; and processes and intermediates for preparing such compounds.
    Type: Grant
    Filed: March 4, 2014
    Date of Patent: December 2, 2014
    Assignee: Theravance Biopharma R&D IP, LLC
    Inventors: Erik Fenster, Melissa Fleury, Adam D. Hughes
  • Patent number: 8901171
    Abstract: The present invention provides a medicament that suppresses (or mitigates) various neurological symptoms caused by a peripheral nerve disorder induced by an anti-cancer agent.
    Type: Grant
    Filed: August 20, 2013
    Date of Patent: December 2, 2014
    Assignee: Takeda Pharmaceutical Company Limited
    Inventor: Naomi Kitamoto
  • Patent number: 8895613
    Abstract: The present invention relates to novel neuraminidase activity inhibitors and use thereof for prophylaxis and treatment of influenza infection, that is to fluorosubstituted4-acetamido-5-guanidino-3-(pentan-3-yloxy)cyclohex-1-enecarboxylic acids and their esters of the general formula 1, pharmaceutically acceptable salts and/or hydrates thereof, wherein R is hydrogen, an optionally substituted C1-C5alkyl, C2-C5alkenyl or C2-C5alkynyl; Rf is CH2F or CHF2. A pharmaceutical composition is provided, a method for its preparation, as well as a method for prophylaxis and treatment of viral diseases.
    Type: Grant
    Filed: April 29, 2013
    Date of Patent: November 25, 2014
    Inventor: Alexandre Vasilievich Ivachtchenko
  • Publication number: 20140343064
    Abstract: The present invention belongs to the field of natural medicine and pharmaceutical chemistry, and specifically relates to novel 2-substituted oleanolic acid derivatives of formula (I) or a pharmaceutically acceptable salt thereof, to a process for the preparation of these compounds, compositions containing such compounds and their use in preparing antineoplastic medicaments.
    Type: Application
    Filed: November 30, 2012
    Publication date: November 20, 2014
    Applicant: Hanghzhou Bensheng Pharmaceutical Co., Ltd
    Inventors: Rongzhen Xu, Frank Rong, Hongxi Lai, Fuwen Xie
  • Publication number: 20140335029
    Abstract: The present invention relates to the use of at least one cyclohexanol derivative of the formula (I) and/or (II) as antimicrobial active compound or as anti-acne, antidandruff, antiperspirant or deodorant active compound, to preparations comprising these compounds, and to specific cyclohexanol derivatives and to a process for the preparation thereof.
    Type: Application
    Filed: December 3, 2012
    Publication date: November 13, 2014
    Applicant: MERCK PATENT GMBH
    Inventors: Thomas Rudolph, Tatjana Mueller
  • Patent number: 8865685
    Abstract: The present invention relates to ophthalmic compositions and methods for the treatment of dry eye and other inflammatory ocular conditions. In particular, the present invention relates to a composition comprising an esterified anti-inflammatory lipid mediator, which is an ester of an anti-inflammatory lipid mediator that is a reaction product of the anti-inflammatory lipid mediator and a polyol wherein the majority of the anti-inflammatory lipid mediator is present in an ester form. In this way, the compositions are substantially free of an acid form of the anti-inflammatory lipid mediators. This composition can be topically delivered to the ocular surface via a preparation, solution, gel, ointment, and/or strip and/or a contact lens.
    Type: Grant
    Filed: June 13, 2012
    Date of Patent: October 21, 2014
    Assignee: Johnson & Johnson Vision Care, Inc.
    Inventor: Annabelle Gallois-Bernos
  • Publication number: 20140309301
    Abstract: The invention provides unit dosage forms, kits, and methods and useful for treating viral infections.
    Type: Application
    Filed: June 24, 2014
    Publication date: October 16, 2014
    Inventors: Yarlagadda S. Babu, Pooran Chand, Shanta Bantia, Shane Arnold, John Michael Kilpatrick
  • Patent number: 8859619
    Abstract: Disclosed are formulations of gamma-hydroxybutyrate in an aqueous medium that are resistant to microbial growth. Also disclosed are formulations of gamma-hydroxybutyrate that are also resistant to the conversion into GBL. Disclosed are methods to treat sleep disorders, including narcolepsy, with these stable formulations of GHB. The present invention also provides methods to treat alcohol and opiate withdrawal, reduced levels of growth hormone, increased intracranial pressure, and physical pain in a patient.
    Type: Grant
    Filed: November 26, 2012
    Date of Patent: October 14, 2014
    Assignee: Jazz Pharmaceuticals, Inc.
    Inventors: Harry Cook, Martha Hamilton, Douglas Danielson, Colette Goderstad, Dayton T. Reardan